Differences

This shows you the differences between two versions of the page.

--- myocarditis [2022/01/06 06:29]
tomk [Pausing Moderna’s COVID Vaccine for Younger Age Groups]
+++ myocarditis [2022/10/09 21:14] (current)
pamela [Myocarditis During the COVID-19 Pandemic]
@@ Line 2: / Line 2: @@
 **Myocarditis** is a condition of inflammation of the [[heart]] muscle, and [[pericarditis]] is inflammation of the outer lining of the heart. Myopericarditis is where both occur simultaneously. In all three cases, the body’s immune system causes inflammation in response to an infection or some other trigger.
-Increased occurrence of myocarditis, pericarditis and myopericarditis has been associated with Covid-19 inoculations, along with Covid-19 infection.
+===== Myocarditis in Animals =====
+Animals other than humans can suffer from myocarditis.
+  * A strain of piscine myocarditis virus infecting Atlantic argentine, Argentina silus (Ascanius)((May, 2012 | T Tengs and I Bockerman | Journal of Fish Diseases | A strain of piscine myocarditis virus infecting Atlantic argentine, Argentina silus (Ascanius) | [[https://www.researchgate.net/publication/225047015_A_strain_of_piscine_myocarditis_virus_infecting_Atlantic_argentine_Argentina_silus_Ascanius|DOI:10.1111/j.1365-2761.2012.01380.x]]))
-===== COVID-19 Pandemic and Vaccines =====
-^             Incidence of Myocarditis Following the Second Dose of a Covid-19 mRNA Vaccine                 ^^^^^^^
+===== Myocarditis During the COVID-19 Pandemic =====
-^  ^  Age 12 - 17  ^  Male Age 12-17  ^  Age 18 - 24  ^  Male Age 18-24  ^  Male Age < 40  ^  Rate from Sars-cov-2  ^
-| Kaiser Permanente Study - Dec 27, 2021((https://www.medrxiv.org/content/10.1101/2021.12.21.21268209v1)) |  1/1860   |  1/2650    |
-| Nature Medicine Paper - Dec 25, 2021((https://www.medrxiv.org/content/10.1101/2021.12.23.21268276v1))|  -  |  -  |  101 excess events per million (Moderna)  |   30 excess events per million  |
-| USA FDA ACIP Meeting Presentation((http://dx.doi.org/10.15585/mmwr.mm7027e2)) |  |  62.8 per million  |   |  50.5 per million  |
+Myocarditis can be caused by Covid-19 infection as well as a side effect of Covid-19 Vaccination (see also [[covid-19_vaccines:adverse_events:myocarditis]]).
+==== Florida Surgeon General Warning ====
+Florida Department of Health sent this bulletin at 10/07/2022 06:12 PM EDT
-===== Mechanisms of Action =====
+{{ ::florida_warning_oct_2022.png?600|}}
+TALLAHASSEE, Fla. – Today, State Surgeon General Dr. Joseph A. Ladapo has announced new guidance regarding mRNA vaccines. The Florida Department of Health (Department) conducted an analysis through a self-controlled case series, which is a technique originally developed to evaluate vaccine safety.
-===== Pausing Moderna’s COVID Vaccine for Younger Age Groups =====
+This analysis found that there is an 84% increase in the relative incidence of cardiac-related death among males 18-39 years old within 28 days following mRNA vaccination. With a high level of global immunity to COVID-19, the benefit of vaccination is likely outweighed by this abnormally high risk of cardiac-related death among men in this age group. Non-mRNA vaccines were not found to have these increased risks.
-On October 6, 2021 Sweden and Denmark said they will pause the use of Moderna’s COVID vaccine for younger age groups after reports of side effects, including myocarditis and pericarditis. Following suit was Finland October 7, Iceland October 8 and France November 8.
+As such, the State Surgeon General recommends against males aged 18 to 39 from receiving mRNA COVID-19 vaccines. Those with preexisting cardiac conditions, such as myocarditis and pericarditis, should take particular caution when making this decision.
+“Studying the safety and efficacy of any medications, including vaccines, is an important component of public health,” said Surgeon General Dr. Joseph Ladapo. “Far less attention has been paid to safety and the concerns of many individuals have been dismissed – these are important findings that should be communicated to Floridians. ((https://web.archive.org/web/20221007232657/https://content.govdelivery.com/accounts/FLDOH/bulletins/3312697))
+=== The analysis can be found here ===
+Exploring the relationship between all-cause and cardiac-related mortality following COVID-19 vaccination or infection in Florida residents: a self-controlled case series study
+Objective - To evaluate the risks of all-cause and cardiac-related mortality following COVID-19 vaccination
+((https://web.archive.org/web/20221007232636/https://floridahealthcovid19.gov/wp-content/uploads/2022/10/20221007-guidance-mrna-covid19-vaccines-analysis.pdf))
+=== The guidance can be found here ===
+Guidance for mRNA COVID-19 Vaccines - October 7, 2022
+Florida continues to emphasize that health care providers review all data to evaluate risks and benefits unique to each patient when determining any health care services to provide, including the administration of [[:COVID-19 vaccines]] containing Messenger RNA (mRNA) which both the [[:Pfizer]] - [[:BioNTech]] and the [[:Moderna]] vaccines utilize.
+The Florida Department of Health (Department) conducted an analysis through a self-controlled case series, which is a technique originally developed to evaluate vaccine safety. This studied mortality risk following mRNA COVID-19 vaccination. This analysis found there is an 84% increase in the relative incidence of cardiac-related death among males 18-39 years old within 28 days following mRNA vaccination. Individuals with preexisting cardiac conditions, such as myocarditis and pericarditis, should take particular caution when considering vaccination and discuss with their health care provider.
+As such, the Florida Department of Health has issued the following guidance ((https://web.archive.org/web/20221007232634/https://floridahealthcovid19.gov/wp-content/uploads/2022/10/20221007-guidance-mrna-covid19-vaccines-doc.pdf))
-France's decision to pause was supported by a study from the French National authority for Health (HAS). ((https://www.epi-phare.fr/rapports-detudes-et-publications/myocardite-pericardite-vaccination-covid19/?fbclid=IwAR2SQ7XguUBiDwVV7mRz_O9hZiO3tmt2yjX8s7R-PvIWv39LBxUCkVGVcKw)) The HAS designed the study by taking cases of hospitalization of myo or pericarditis in inoculated people and matched them each to controls of similar age, sex & geography. They adjusted for history of myocarditis or pericarditis, history of SARS-CoV-2 infection etc. Essentially, they defined a signal (hospitalization for myo/peri within 7 days of inoculation of either Moderna or Pfizer) and compared it to a baseline (control of unvaxxed & uninfected).
-What they found was for the second dose of Moderna for men under 30 (within 7 days of inoculation) an excess of hospitalization cases from myocarditis alone reaching ~131 per million doses. They also calculated an odds-adjusted ratio or OR (which is basically a multiple of the signal over baseline occurrence). 2-dose Moderna for men below 30 had an OR of ~80x (which is like saying 80x more risk vs. baseline) for myocarditis alone. For comparison SARS-CoV-2 infection in the previous month for myocarditis had a OR of ~7.9x.
-Woman under 30 on the second dose of Moderna found an excess of 37 per million doses for myocarditis with an OR of ~40.6x. For Pfizer & myocarditis alone, men under 30 for the second doses found excess hospitalizations of 27 per million doses and an OR of ~10.9x, while woman saw an increase of 4 per million doses and an OR of ~11.4x.